Originally approved for children with spinal muscular atrophy aged 2 months and older, risdiplam is now indicated for presymptomatic children younger than 2 months.
The mother of two had been struggling to breastfeed her 1-month-old daughter ever since she was born, when the hospital gave the baby formula first without consulting her on her desire to breastfeed.